Avricore Health Inc. (TSXV:AVCR,OTCQB:AVCRF) has launched its campaign on the Investing News Network’s life sciences channel. Avricore Health is currently focussed on the neutraceutical, medical cannabis and endocannabinoid industries. The company is also in development of HealthTab™, a point-of-care screening system that enables patients to monitor themselves, screening for 21 biomarkers of chronic disease. The HealthTab™ system has been certified by Health Canada and is currently in use by doctors, physicians and medical professionals across the country.

In addition to the company’s HealthTab™ platform, Avricore Health also offers an over-the-counter iron supplement called Hema-FerTM that is available at London Drugs stores throughout British Columbia and Alberta. Avricore generated over $400,000 in sales in 2018, a total the company expects to eclipse by more than double in 2019 as it expands into Atlantic Canada and Quebec.


Avricore Health’s company highlights include the following:

  • Global pharmaceuticals market to reach $1.17 trillion by 2021.
  • Focused on serving the nutraceutical, medical cannabis and endocannabinoid industries.
  • Charges $350 for software installation and a monthly fee for the use of the equipment.
  • HealthTab™ can directly measure and monitor the 21 key biomarkers of chronic diseases.
  • Utilizes Abaxis’ Piccolo Xpress® point of care analyzer, which was initially designed by NASA to test the health of its astronauts.
  • Hema-FerTM generated $400,000 in sales in 2018 and has an 81 percent profit margin.
  • Partnerships and agreements in place with FoodRocket, Molecular You Corporation and Emerald Health Therapeutics.
  • Approximately 60 percent of Avricore Health’s shareholders are institutional.
  • Led by a strong board of directors and advisory team.

Click here to see the educational profile for Avricore Health Inc. (TSXV:AVCR,OTCQB:AVCRF) and to request an investor presentation. 

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less